Blog

John J Collins: C-POST Trial Results – Adjuvant Immunotherapy in Cutaneous SCC by Dr. Danny Rischin

John J Collins and Danny Rischin

Jul 10, 2025, 09:18

John J Collins: C-POST Trial Results – Adjuvant Immunotherapy in Cutaneous SCC by Dr. Danny Rischin

John J Collins, CO-Founder at MedInsights Unleashed, shared a post by MedInsights Unleashed, on LinkedIn:

“New Episode Alert: C-POST Trial Results: Adjuvant Immunotherapy (Cemiplimab) in Cutaneous SCC by Dr. Danny Rischin, MD

Hi everyone, I hope you all had a fantastic 4th of July!

I had the opportunity to attend ASCO this year and was in the audience when Dr. Danny Rischin, MD presented the C-POST trial data. Thanks to Sam Misir, and Matthew Fury, I was fortunate to meet with Dr. Rischin, the lead investigator of this important trial.

With a family history of skin cancer, I found the C-POST study results particularly meaningful, they are stellar, offering new hope to patients living with cutaneous squamous cell carcinoma (CSCC). Dr. Rischin, MD, explains how this latest research could truly make a difference for those facing high-risk or advanced CSCC.

Listen here.

Thank you all again for your support of MedInsights Unleashed.

Kind regards, John.”

Quoting MedInsights Unleashed‘s post:

“New Episode Alert: C-POST Trial Results: Adjuvant Immunotherapy (Cemiplimab) in Cutaneous SCC by Dr. Danny Rischin, MD

We’re excited to share important progress in skin cancer treatment on the latest episode of MedInsights Unleashed, with Dr. Danny Rischin, MD, Medical Oncologist at the Peter MacCallum Cancer Center and Professor at the Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia

Key insights from the C-POST trial:

First trial to show adjuvant immunotherapy (cemiplimab) after surgery significantly improves disease-free survival in high-risk cutaneous squamous cell carcinoma (CSCC).

Disease-free survival at 2 years: 64% (placebo) vs 87% (cemiplimab) — with manageable side effects.

68% reduction in recurrence risk for high-risk patients.
Fewer recurrences = better quality of life, less need for disfiguring salvage treatments.

Sets a new standard in CSCC care and points to the future of neoadjuvant immunotherapy.

For patients:

If you have high-risk CSCC, adjuvant immunotherapy can lower your chance of the cancer coming back – cemiplimab reduced recurrence risk by 68% in the study.

Ask your doctor about your personal risk – new risk models help identify who benefits most from extra treatment beyond surgery.

Prevention still matters, even with better treatments, sun protection remains the best way to avoid skin cancer in the first place.

Listen now to hear how the C-POST trial offers new hope for CSCC patients.

Reminder: As always, the content of MedInsights Unleashed podcast is for informational purposes only and should not be considered as medical advice. Please consult your healthcare provider for personal guidance.

Thank you for all your support.

John J Collins MBA EMT and Zahra Ramji.”

More posts featuring Adjuvant Immunotherapy on OncoDaily.

adjuvant immunotherapy cancer cemiplimab Cutaneous SCC Danny Rischin John J Collins MedInsights Unleashed neoadjuvant immunotherapy OncoDaily Oncology

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care